Molnupiravir: Perbedaan antara revisi

{{penjelasan singkat|Obat antivirus}}

{{Infobox drug

| width =

| alt =

 

<!-- Clinical data -->

| ATC_prefix = None

| ATC_suffix =

 

<!-- Legal status -->

| elimination_half-life =

| duration_of_action =

 

<!-- Identifiers -->

== Efek samping ==

Ditemukan efek samping dalam studi MOVe-OUT fase III yakni diare (2%), mual (1%) dan pusing (1%), semua gejala ini termasuk gejala ringan atau sedang.<ref name=":1" />

 

<!-- belum diterjemahkan In March 2020, the research team pivoted to studying [[SARS-CoV-2]], and successfully used the drug to treat human cells infected with the novel coronavirus.<ref name="Halford2020" /> Plemper's group published in the journal ''[[Nature Microbiology]]'' the first demonstration that molnupiravir is orally active against SARS-CoV-2 in an animal model and established proof-of-concept that treatment completely suppresses virus transmission to untreated contacts within 24 hours.<ref>{{cite journal | vauthors = Cox RM, Wolf JD, Plemper RK | title = Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets | journal = Nature Microbiology | volume = 6 | issue = 1 | pages = 11–18 | date = January 2021 | pmid = 33273742 | pmc = 7755744 | doi = 10.1038/s41564-020-00835-2 }}</ref>